Intrinsic Therapeutics Stock
Develops therapies to treat disc herniations in the spine for discectomy patients
Sign up today and learn more about Intrinsic Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Intrinsic Therapeutics Stock
Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.
Funding History
| January 2001 | $7.2M |
|---|---|
| December 2002 | $25.0M |
| September 2007 | $21.0M |
| February 2010 | $18.0M |
| November 2012 | $11.6M |
| September 2014 | $17.3M |
| December 2016 | $17.9M |
| May 2017 | $28.0M |
| May 2017 | $21.0M |
| April 2019 | $52.0M |
Management
Vice President, Global Sales
Remco Maljers
CFO
David Neafus
Founder & Executive Director
Gregory Lambrecht
Vice President, Global Marketing
Ivo Scheepens
President and CEO
Cary Hagan
Chief Operating Officer
Jacob Einhorn
Press
prnewswire - Jun, 14 2019
NYU Langone Performs First U.S. Procedure with Newly Approved Device to Reduce Herniated Disc Recurrencebusinesswire - Mar, 1 2019
Anaconda Biomed Expands Leadership Team with Two New Senior Hiresmassdevice - Feb, 13 2019
Intrinsic Therapeutics wins PMA for Barricaid spinal implant despite safety concernsmassdevice - Feb, 13 2019
Intrinsic Therapeutics wins PMA for Barricaid spinal implant despite safety concernsprnewswire - May, 24 2018
Pivotal Clinical Trial Demonstrates Superiority of Anular Closure Compared to Standard Lumbar Discectomymassdevice - Sep, 29 2015
AdvaMed snags Boston Scientific’s Wetzel for assistant GCprnewswire - Sep, 29 2015
Spinal Fusion Market 2015 Product Pipeline Review Reportmassdevice - Sep, 29 2015
Medigus secures $5.6M in funding, reveals positive outcomes from study of its MUSE surgical endostapling device | Medtech funding for the week of September 15, 2014massdevice - Sep, 29 2015
Intrinsic Therapeutics raises $17.2M for spinal surgery devicesxconomy - May, 21 2015
Massachusetts Startups Held Their Own in February---Upwards of $200 Million Invested in 26 Deals | Xconomyxconomy - May, 21 2015
Intrinsic Therapeutics Grabs $18M | Xconomyventurebeat - May, 20 2015
Life sciences briefing: Monday, Sept. 17, 2007 | VentureBeat | News | by David P. HamiltonEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
